AcelRx Pharmaceuticals (ACRX) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a hold rating to a buy rating in a research note issued to investors on Tuesday. The firm currently has $2.75 price objective on the specialty pharmaceutical company’s stock.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

Separately, ValuEngine raised AcelRx Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $4.96.



Shares of ACRX stock opened at $2.80 on Tuesday. AcelRx Pharmaceuticals has a one year low of $2.60 and a one year high of $2.92. The company has a current ratio of 4.05, a quick ratio of 4.57 and a debt-to-equity ratio of -0.20.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.78 million. equities research analysts predict that AcelRx Pharmaceuticals will post -0.85 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new position in AcelRx Pharmaceuticals in the first quarter valued at approximately $113,000. Virtu Financial LLC acquired a new position in AcelRx Pharmaceuticals in the fourth quarter valued at approximately $120,000. Northern Trust Corp lifted its stake in AcelRx Pharmaceuticals by 60.8% in the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 34,584 shares during the period. Finally, Geller Family Office Services LLC lifted its stake in AcelRx Pharmaceuticals by 175.0% in the fourth quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock valued at $557,000 after buying an additional 175,000 shares during the period. 9.14% of the stock is currently owned by hedge funds and other institutional investors.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply